The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses
Abstract
Non-natural modifications are widely introduced into peptides to improve their therapeutic efficacy, but their impact on immunogenicity remains largely unknown. As the CD4 T-cell response is a key factor in triggering immunogenicity, we investigated the effect of introducing D-amino acids (Daa), amino isobutyric acid (Aib), N-methylation, C α -methylation, reduced amide, and peptoid bonds into an immunoprevalent T-cell epitope on binding to a set of HLA-DR molecules, recognition, and priming of human T cells. Modifications are differentially accepted at multiple positions, but are all tolerated in the flanking regions. Introduction of Aib and Daa in the binding core had the most deleterious effect on binding to HLA-DR molecules and T-cell activation. Their introduction at the positions close to the P1 anchor residue abolished T-cell priming, suggesting they might be sufficient to dampen peptide immunogenicity. Other modifications led to variable effects on binding to HLA-DR molecules and T-cell reactivity, but none exhibited an increased ability to stimulate T cells. Altogether, non-natural modifications appear generally to diminish binding to HLA-DR molecules and hence T-cell stimulation. These data might guide the design of therapeutic peptides to make them less immunogenic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peptides As Therapeutics with Enhanced Bioactivity
Goodwin, D., Simerska, P., & Toth, I. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803251548 · Cited by 176
Flagged first, then by citations
Research works printed but not linked: 46
- Usmani, 2017, THPdb: database of FDA-approved peptide and protein therapeutics, PLoS ONE, 12, e0181748, 10.1371/journal.pone.0181748 · DOI
- Gentilucci, 2010, Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization, Curr Pharm Des, 16, 3185, 10.2174/138161210793292555 · DOI
- Dingman, 2019, Immunogenicity of protein pharmaceuticals, J Pharm Sci, 108, 1637, 10.1016/j.xphs.2018.12.014 · DOI
- Jaton, 1968, Role of optical configuration in the immunogenicity and specificity of synthetic antigens derived from multichain polyproline, J Biol Chem., 243, 5616, 10.1016/S0021-9258(18)91912-5 · DOI
- Benkirane, 1993, Antigenicity and immunogenicity of modified synthetic peptides containing D-amino acid residues. Antibodies to a D-enantiomer do recognize the parent L-hexapeptide and reciprocally, J Biol Chem, 268, 26279, 10.1016/S0021-9258(19)74312-9 · DOI
- Dintzis, 1993, A comparison of the immunogenicity of a pair of enantiomeric proteins, Proteins, 16, 306, 10.1002/prot.340160309 · DOI · Paper page
- Maillère, 1995, Probing immunogenicity of a T cell epitope by L-alanine and D-amino acid scanning, Mol Immunol, 32, 1073, 10.1016/0161-5890(95)00073-9 · DOI
- Cotton, 1998, Pseudopeptide ligands for MHC II-restricted T cells, Int Immunol, 10, 159, 10.1093/intimm/10.2.159 · DOI
- Jawa, 2013, T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation, Clin Immunol, 149, 534, 10.1016/j.clim.2013.09.006 · DOI
- Koren, 2007, Clinical validation of the in silico prediction of immunogenicity of a human recombinant therapeutic protein, Clin Immunol, 124, 26, 10.1016/j.clim.2007.03.544 · DOI
- Sturniolo, 1999, Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices [see comments], Nat Biotechnol, 17, 555, 10.1038/9858 · DOI
- Wang, 2008, A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach, PLoS Comput Biol, 4, e1000048, 10.1371/journal.pcbi.1000048 · DOI
- Hill, 1994, Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401, J Immunol, 152, 2890, 10.4049/jimmunol.152.6.2890 · DOI
- Gurunath, 1995, Enhancing peptide antigenicity by helix stabilization, FEBS Lett, 361, 176, 10.1016/0014-5793.(95)00166-7 · DOI
- Bossus, 1997, Improved detection of human antibodies to a Plasmodium antigen using a peptide modified with Aib residues, J Pept Sci., 3, 47, 10.1002/(sici)1099-1387(199701)3:1<47::aid-psc80>3.0.co;2-v · DOI
- de Haan, 2002, Major histocompatibility complex class II binding characteristics of peptoid-peptide hybrids, Bioorg Med Chem, 10, 1939, 10.1016/S0968-0896(01)00434-5 · DOI
- Ettouati, 1996, Substitution of peptide bond 53-54 of HEL(52-61) with an ethylene bond rather than reduced peptide bond is tolerated by an MHC-II restricted T cell, Pept Res, 9, 248
- Bastian, 2004, Characterization of a reduced peptide bond analogue of a promiscuous CD4 T cell epitope derived from the Plasmodium falciparum malaria vaccine candidate merozoite surface protein 1, Mol Immunol, 41, 775, 10.1016/j.molimm.2004.04.019 · DOI
- Texier, 2000, HLA-DR restricted peptide candidates for bee venom immunotherapy, J Immunol, 164, 3177, 10.4049/jimmunol.164.6.3177 · DOI
- Texier, 2001, Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules, Eur J Immunol., 31, 1837, 10.1002/1521-4141(200106)31:6<1837::AID-IMMU1837>3.0.CO;2-H · DOI
- Marshall, 1994, Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands, J Immunol, 152, 4946, 10.4049/jimmunol.152.10.4946 · DOI
- Gelder, 1995, Human CD4+ T-cell repertoire of responses to influenza A virus hemagglutinin after recent natural infection, J Virol, 69, 7497, 10.1128/JVI.69.12.7497-7506.1995 · DOI
- Stern, 1994, Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide, Nature, 368, 215, 10.1038/368215a0 · DOI
- Hennecke, 2002, Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity, J Exp Med., 195, 571, 10.1084/jem.20011194 · DOI
- Cohen, 2006, Scanning the HIV genome for CD4+ T cell epitopes restricted to HLA-DP4, the most prevalent HLA class II molecule, J Immunol, 176, 5401, 10.4049/jimmunol.176.9.5401 · DOI
- Castelli, 2007, Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins, Eur J Immunol, 37, 1513, 10.1002/eji.200636783 · DOI
- Castelli, 2008, Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively, Eur J Immunol, 38, 2821, 10.1002/eji.200738072 · DOI
- Gallais, 2020, Large-scale mapping of the Ebola NP and GP proteins reveals multiple immunoprevalent and conserved CD4 T-cell epitopes, Cell Mol Immunol, 10.1038/s41423-020-0455-2 · DOI
- Chaux, 1999, Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes, J Exp Med, 189, 767, 10.1084/jem.189.5.767 · DOI
- Wang, 2008, Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients, J Immunol, 181, 431, 10.4049/jimmunol.181.1.431 · DOI
- Hamze, 2017, Characterization of CD4 T cell epitopes of infliximab and rituximab identified from healthy donors, Front Immunol, 8, 500, 10.3389/fimmu.2017.00500 · DOI
- Meunier, 2019, Impact of human sequences in variable domains of therapeutic antibodies on the location of CD4 T-cell epitopes, Cell Mol Immunol, 17, 656, 10.1038/s41423-019-0304-3 · DOI
- Castelli, 2013, Hierarchy of CD4 T cell epitopes of the ANRS Lipo5 synthetic vaccine relies on the frequencies of pre-existing peptide-specific T cells in healthy donors, J Immunol, 190, 5757, 10.4049/jimmunol.1300145 · DOI
- Moon, 2007, Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude, Immunity, 27, 203, 10.1016/j.immuni.2007.07.007 · DOI
- Kwok, 2012, Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire, J Immunol, 188, 2537, 10.4049/jimmunol.1102190 · DOI
- King, 1994, Structure-immunogenicity relationship of melittin, its transposed analogues, and D-melittin, J Immunol, 153, 1124, 10.4049/jimmunol.153.3.1124 · DOI
- Zavala-Ruiz, 2003, Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1, J Biol Chem, 278, 44904, 10.1074/jbc.M307652200 · DOI
- Chicz, 1993, Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles, J Exp Med, 178, 27, 10.1084/jem.178.1.27 · DOI
- Aravinda, 2008, Aib residues in peptaibiotics and synthetic sequences: analysis of nonhelical conformations, Chem Biodivers, 5, 1238, 10.1002/cbdv.200890112 · DOI
- Karosiene, 2013, NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ, Immunogenetics., 65, 711, 10.1007/s00251-013-0720-y · DOI
- Vita, 2015, The immune epitope database (IEDB) 3.0, Nucleic Acids Res, 43, D405, 10.1093/nar/gku938 · DOI
- Stern, 1992, The human class II MHC protein HLA-DR1 assembles as empty alpha beta heterodimers in the absence of antigenic peptide, Cell, 68, 465, 10.1016/0092-8674.(92)90184-E · DOI
- Jardetzky, 1990, Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding, Embo J, 9, 1797, 10.1002/j.1460-2075.1990.tb08304.x · DOI
- Vogt, 1994, Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides, J Immunol, 153, 1665, 10.4049/jimmunol.153.4.1665 · DOI
- Geluk, 1994, HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs, J Immunol, 152, 5742, 10.4049/jimmunol.152.12.5742 · DOI
- Davenport, 1995, Naturally processed peptides from two disease-resistance-associated HLA- DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR beta chain, Proc Natl Acad Sci USA, 92, 6567, 10.1073/pnas.92.14.6567 · DOI
Metadata
- Authors
- Azam, A., Mallart, S., Illiano, S., Duclos, O., Prades, C., & Maillère, B.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-03-11
- Volume
- 12
- ISSN
- 1664-3224
- Cited by
- 22
- References
- 1
- Funders
- Commissariat à l’Énergie Atomique et aux Énergies Alternatives
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review